Cyrano Therapeutics

Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia) – Copy

There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition Delray Beach, FL, October 12, 2023 – Cyrano Therapeutics, Inc., a regenerative medicine company pioneering the development of treatments for smell loss, announced today that it has commenced enrollment in the Phase 2 FLAVOR trial,  a randomized, double-blinded, placebo-controlled, multi-dose clinical trial of […]